21. personalised therapy Flashcards
why is there a push for more focused therapies?
unlike chemo and radiotherapy, these discriminate between healthy and diseased tissue
leukaemia is uncontrolled haematopoiesis, what variation can there be of this?
> chronic - slow killer
acute - fast killer
lymphoblastic or myelogenous
what cells do CLP give rise to? what cells do CMP give rise to?
give rise to cells which are to do with antibodies
>everything else in the blood
what happens when there is deregulation of either CLP or CMP?
these churn out lots of mutant cells and clog up the blood = leukaemia
how many people are affected by CML and how curable is it
about 500 new cases a year in UK
quite curable
what age do people get CML
late onset – patients with CML tend to be around 65/70 years old
how does the age of people with CML affect potential therapeutics?
full body radiation to kill all BMSC and then have a SC operation is major even for young people
in addition to age what else may hinder using SC operation for CML
finding donors is hard
how long does the chronic phase of CML last? and what does this result in?
4 or 5 years - only produce a few extra non red cells in circulation and so only symptom is fatigue
what happens after chronic phase of CML?
cell division is increased and the bone marrow fills up with abnormal progenitor cells - this is the accelerated phase which last 6 - 18 months
what follows the accelerated phase of CML?
the blast phase lasts 4 - 6 months - the bone marrow cells enter circulation and being diving in circulation. this leads to fatality
how can CML be detected?
using blood smears
>this shows ratio of red cells to non-red cells which should be 1000:1
what percentage of CML are homogenous?
80-95%
what causes CML?
translocation between chromosome 9 and 22
what gene is on chromosome 9?
abl
what gene is on chromosome 22?
BCR - unknown function
relatively how much of BCR and abl are in the fusion protein?
little bit of BCR and a lot of abl
describe abl
> tyrosine kinase
>located in nucleus
what happens when abl is fused to BCR?
the kinase is constitutively active and now localised in the cytoplasm (away from its normal substrates)
>acts as surrogated activated TKR - recruits proteins in signalling pathways e.g. switches on AKT and prevents apoptosis
what does BCR-abl influence?
proliferation, apoptosis, adhesion and motility
BCR-abl added into mice in the appropriate cell compartment and these mice get a CML like disease, what happens when this is removed?
they are cured
name a potential inhibitor for kinase BCR-abl
Gleevec
how does the abl tyrosine kinase differ from other kinases? and how many other kinases are like this?
it has an ATP binding site like a channel rather than a pocket
>there are only 4 or 5 other kinases like this
what was shown in phase 1 of gleevec drugs trial?
the drug was shown to inhibit abl in healthy patients without bad side effects
>established the dose
>saw how long it stays in body and determined can be given two times a day
what happens in phase 2?
people with CML are given Gleevec
following gleevec treatment, what percentage of people with CML had normal haematological smears?
> 95% of patients have in the chronic phase of disease
>30% in blasts
what percentage of could chromosome abnormalities no longer be observed in and why is this?
60% of people in chronic phase
>cells which have abnormal chromosomes died i.e. cells were addicted to this oncogene
why was phase 3 skipped?
there was no other treatment to compare it with